ReviewWorld journal of gastroenterology2006
Molecular therapy for hepatic injury and fibrosis: where are we?
Review in World journal of gastroenterology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 75 citations in OpenAlex.
- Role of hepatic stellate cells in liver ischemia-reperfusion injury.Frontiers in immunology · 2022Review
- Beneficial and Deleterious Effects of Female Sex Hormones, Oral Contraceptives, and Phytoestrogens by Immunomodulation on the Liver.International journal of molecular sciences · 2019Review
- Article
- Liver Macrophage Depletion Ameliorates The Effect of Mesenchymal Stem Cell Transplantation in a Murine Model of Injured Liver.Scientific reports · 2019Article
- Therapeutic potential effect of bone marrow-derived mesenchymal stem cells on chronic liver disease in murineJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2018Article
- Importance of detoxifying enzymes in differentiating fibrotic development between SHRSP5/Dmcr and SHRSP rats.Environmental health and preventive medicine · 2016Article
- Targeting the PDGF-B/PDGFR-β Interface with Destruxin A5 to Selectively Block PDGF-BB/PDGFR-ββ Signaling and Attenuate Liver Fibrosis.EBioMedicine · 2016Article
- Moderate (2%, v/v) Ethanol Feeding Alters Hepatic Wound Healing after Acute Carbon Tetrachloride Exposure in Mice.Biomolecules · 2016Article
- Evolving Insights on Metabolism, Autophagy, and Epigenetics in Liver Myofibroblasts.Frontiers in physiology · 2016Review
- Reversibility and heritability of liver fibrosis: Implications for research and therapy.World journal of gastroenterology · 2015Review
- IL-17A G197A gene polymorphism contributes to susceptibility for liver cirrhosis development from patients with chronic hepatitis B infection in Chinese population.International journal of clinical and experimental medicine · 2015Article
- PDGFRα in liver pathophysiology: emerging roles in development, regeneration, fibrosis, and cancer.Gene expression · 2015Review
- Small RNA- and DNA-based gene therapy for the treatment of liver cirrhosis, where we are?World journal of gastroenterology · 2014Review
- Article
- Involvement of DNA damage response pathways in hepatocellular carcinoma.BioMed research international · 2014Review
- Corn peptides protect against thioacetamide-induced hepatic fibrosis in rats.Journal of medicinal food · 2013Article
- Effects of Fufang Biejia Ruangan pills on hepatic fibrosis in vivo and in vitro.World journal of gastroenterology · 2013Article
- Evaluation of the Chinese Medicinal Herb, Graptopetalum paraguayense, as a Therapeutic Treatment for Liver Damage in Rat Models.Evidence-based complementary and alternative medicine : eCAM · 2012Article
- Cell fusion reprogramming leads to a specific hepatic expression pattern during mouse bone marrow derived hepatocyte formation in vivo.PloS one · 2012Article
- Time course of gene expression profiling in the liver of experimental mice infected with Echinococcus multilocularis.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Hepatic fibrosis is a wound healing response, involving pathways of inflammation and fibrogenesis. In response to various insults, such as alcohol, ischemia, viral agents, and medications or hepatotoxins, hepatocyte damage will cause the release of cytokines and other soluble factors by Kupffer cells and other cell types in the liver. These factors lead to activation of hepatic stellate cells, which synthesize large amounts of extracellular matrix components. With chronic injury and fibrosis, liver architecture and metabolism are disrupted, eventually manifesting as cirrhosis and its complications. In addition to eliminating etiology, such as antiviral therapy and pharmacological intervention, it is encouraging that novel strategies are being developed to directly address hepatic injury and fibrosis at the subcellular and molecular levels. With improvement in understanding these mechanisms and pathways, key steps in injury, signaling, activation, and gene expression are being targeted by molecular modalities and other molecular or gene therapy approaches. This article intends to provide an update in terms of the current status of molecular therapy for hepatic injury and fibrosis and how far we are from clinical utilization of these new therapeutic modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.